Conclusion
In the present clinical case, a drug-induced prolongation of the QT
interval was identified, which led to the clinical death of the patient.
When prescribing a drug that can increase the duration of the QT
interval, patients should be warned about the need to promptly inform
the attending physician about any symptoms that they may have. Possible
manifestations of ”Torsade de Pointes” are fainting, paroxysmal heart
rhythm disturbances, especially recently developed, palpitations and
pre-syncope, pre-syncope without palpitations. To identify the risk of
developing heart failure, a regular electrocardiographic examination is
necessary. The latent lengthening of the QT interval is greater than
500ms. Thus, when prescribing drugs, it is necessary to remember the
possibility of increasing the risk of death of patients. Besides, it is
necessary to take into account the increase in the likelihood of
developing TdP and monitor the duration of the QT interval.
Hematologists must be fully aware of possible cardiac arrhythmias, and
close collaboration between cardiologists and hematologists will lead to
better cardiovascular risk stratification, monitoring, and treatment.